Entering text into the input field will update the search result below

CRISPR Therapeutics' (CRSP) CEO Samarth Kulkarni on 4th Annual Evercore ISI HealthCONx Conference

Dec. 01, 2021 4:20 PM ETCRISPR Therapeutics AG (CRSP)1 Comment
SA Transcripts profile picture
SA Transcripts

CRISPR Therapeutics (NASDAQ:CRSP) 4th Annual Evercore ISI HealthCONx Conference December 1, 2021 12:35 PM ET

Company Participants

Samarth Kulkarni – Chief Executive Officer

Conference Call Participants

Liisa Bayko – Evercore ISI

Liisa Bayko

Hi, good afternoon. This is Liisa Bayko, biotech analyst at Evercore ISI. I’m very pleased to be joined today by one of the leading CRISPR companies, CRISPR. Today, we have CEO, Sam joining me to discuss the company’s suite of products. Sam, I just want start off by a broad question, CRISPR technology takes many forms and you’ve sort of chosen to start with sort of the CAR-T, and ex vivo sort of approaches. And then moving on to some other interesting sort of cell therapies, other people have gone different routes, like in vivo, for example. Can you discuss, why you decided to start in the way you did? And what’s your strategy in bringing CRISPR to market?

Samarth Kulkarni

Yeah, thanks for having us Liisa, and it’s always fun to be at this conference, which we’ve been doing for the last four years. I think it’s a space that’s evolving quite rapidly with CRISPR. I think when you back in the early 80s, when you saw companies go after antibodies, you had many different strategies that each company is spouse. And that was one of the big differences between success and failure is the way you build and shape your portfolio. Broadly early on, there was this question of ex vivo versus in vivo, and the two different approaches to use CRISPR. And we decided we wanted to play in both areas. The question was, how do you prioritize? And how do you move things first versus second?

And in terms of our strategy, what we want to do is, we operate in franchises and we want

Recommended For You

Comments (1)

This stock has taken a beaten but I'm more excited than ever holding CRSP after listening to this conference. A really exciting portfolio of potential products.
To report an error in this transcript, .Contact us to add your company to our coverage or use transcripts in your business. Learn more about Seeking Alpha transcripts here. Your feedback matters to us!

About CRSP

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on CRSP

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.